FRAMINGHAM, Mass., Aug. 28 /PRNewswire-FirstCall/ -- StatSure Diagnostic Systems, Inc. is pleased to announce that the results of the studies done at the National Public Health Institute of Finland, (Helsinki, Finland) whereby StatSure's Saliva Sampler(TM) was chosen as the standard for sampling oral fluid / saliva in all tasks in DRUID (EU funded research project Driving Under Influence of Drugs, alcohol and medicines), are being presented at TIAFT Conference (The International Association of Forensic Toxicologists) in Seattle this week.
The aim of the study was to investigate the best oral fluid collection device that is:
Suitable for roadside collection (fast, easy to use) Provides enough sample for toxicological analysis Sample volume can be measured Recovery and stability of drugs and medicinal drugs is very good.
The investigated devices were Greiner Bio-One, Orasure Intercept(R), Immunalysis Quantisal(TM), StatSure Saliva Sampler(TM), Cozart(R), SarstedtSalivette(R), Malvern Medical OraCol, Acro Biotech Salicule, Varian OraTube(TM).
The overall recovery of the analytes, after the whole sampling process, is of primary importance when selecting an oral fluid collection device for toxicological analysis. Considerable differences in the overall reliability of oral fluid collection devices were noted. The results of the study emphasize the impact of the selection of the oral fluid collection device on the whole toxicological procedure. StatSure's Saliva Sampler(TM) gave best results for recovery (>80% for all substances), for stability, was quick to use(<2min collection time), and got good user comments.
As a result of being chosen by DRUID, StatSure has been receiving initial purchase orders from twelve countries throughout Europe.
For a copy of the complete report, please visit the following link on our website: http://statsure.com/TIAFT_OF_collection_devices.pdf
About StatSure:
StatSure Diagnostic Systems, Inc. is engaged in the development, manufacture and marketing of rapid immunoassay tests for the detection of sexually transmitted and other infectious diseases; in addition, the Company has developed and is marketing a product line of patented, oral- fluid collection devices. The Company's proprietary platforms provide significant customer benefits and competitive advantages as compared to similar products that are currently available. Improved accuracy, operator convenience, and reduced risk of infection from collecting and handling specimens, have been engineered into SDS products. All of the company's diagnostic tests are based on the same easy-to-use technology platform, thus facilitating the development of future products. Certain of these products are sold in the United States as well as internationally to various distributors for use in clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations.
Forward-Looking Statements
Statements contained herein that are not historical facts are forward- looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties.
Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing and the demand for the Company's products. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC").
StatSure Diagnostic Systems, Inc.CONTACT: StatSure Diagnostic Systems, Inc., +1-508-872-2625
Web site: http://www.statsure.com/
